New Treatments On the Horizon for Intracranial Hypertension

In this interview from NANOS 2021, Dr. Julie Falardeau describes promising new treatments for the treatment of idiopathic intracranial hypertension. She highlights efficacy and safety data for a glucagon-like peptide-1 (GLP-1) agonist and a 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor.  

Relevant Financial Disclosures: None